Alexandria (ARE) boosts investors' confidence with a dividend hike of 2.4%. Robust operating results, a decent financial position and a lower payout ratio make the dividend rate sustainable.
Alexandria Real Estate Equities, Inc. is a REIT that focuses on markets in the medical, pharmaceutical, and biopharmaceutical industries. Despite not being cheap, the company's rapid growth and low leverage make it a worthwhile investment. Revenue and profitability metrics have shown consistent growth, and the company's market has a positive outlook for continued expansion.
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Alexandria Real Estate Equities (ARE) have what it takes?
Higher interest rates have decreased investor interest in utilities and real estate, but we believe some companies are being unfairly punished. Despite the challenges facing traditional office REITs, Alexandria has maintained a strong financial performance, benefiting from its strategic locations and the growing demand for life sciences real estate. Alexandria offers an interesting opportunity for long-term investors, driven by robust R&D spending in the bio-pharma industry, and an attractive valuation.
Investing in demographic trends is a particular interest of mine. Alexandria Real Estate's revenue and FFO per share climbed in Q1. The company's balance sheet is well-capitalized.